A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs BTA 074 (Primary)
- Indications Genital warts
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Anaconda Pharma
- 04 Apr 2017 According to an Aviragen Therapeutics media release, the company anticipates top-line efficacy data in the first half of 2018.
- 04 Apr 2017 According to an Aviragen Therapeutics media release, the company anticipates to complete the enrolment in this trial in the second half of 2017.
- 03 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2018.